(Reuters) -Sanofi plans to seek U.S. approval for its best-selling anti-inflammatory drug Dupixent to be used in the treatment of "smoker's lung", also known as COPD, after a second large trial showed ...
RegRegon Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent for treating moderate-to-severe chronic spontaneous urticaria in patients aged 12 and above who do ...
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...
May 31 (Reuters) - Sanofi (SASY.PA), opens new tab and partner Regeneron Pharmaceuticals (REGN.O), opens new tab have secured the European regulator's backing for use of Dupixent in patients with a ...
TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing ...
The eczema drug is already approved for patients 12 and older; this proposal would allow it to be prescribed to those as young as 6. Sanofi and Regeneron already market Dupixent in the U.S. for use by ...
A diagnosis of T-cell lymphoma after using Dupixent raises serious questions for patients and families. Many want clear answers about whether they may have a legal claim and what criteria determine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback